Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of thioimidazolidinone medicine for treating COVID-19 diseases

A technology of thioimidazolidinone and uses, applied in the field of antiviral drugs, can solve the problems of incomplete protection, low efficiency of antibody inhibition and the like

Active Publication Date: 2021-07-23
SUZHOU KINTOR PHARMA
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Furthermore, these variants were less efficiently suppressed by antibodies from recovered patients and vaccinated
Therefore, recovery from COVID-19 and vaccination may only provide incomplete protection against these virus variants

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of thioimidazolidinone medicine for treating COVID-19 diseases
  • Application of thioimidazolidinone medicine for treating COVID-19 diseases
  • Application of thioimidazolidinone medicine for treating COVID-19 diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0036] The invention can be further understood by the examples, however, it is to be understood that these examples do not limit the invention. Variations of the invention now known or further developed are considered to fall within the scope of the invention described herein and claimed below.

[0037] Unless otherwise specified in the examples, the crystal form of thioimidazolidinone with the structure of formula (I-A) is Form A, and its preparation method can be completed according to the teaching in CN 201510861715.0.

[0038] 1. Effect of thioimidazolidinone of formula (I-A) structure on Lncap, ACE2 and TMPRSS2 protein expression in A549 cells

[0039] Western-blot method was used to detect the degradation effect of thioimidazolidinone with the structure of formula (I-A) on ACE2 and TMPRSS2 proteins in prostate cancer cell line LnCap and lung cancer cell A549.

[0040] 1.1 Experimental materials

[0041] cell source culture medium lncap Chinese Acad...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
absorbanceaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the technical field of medicines, and particularly relates to application of a thioimidazolidone medicine or pharmaceutically acceptable salt thereof to preparation of a medicine for treating ACE2 and TMPRSS2 protein disorder related diseases, in particular to application to preparation of a medicine for treating COVID-19 diseases.

Description

technical field [0001] The invention belongs to the technical field of antiviral drugs, and in particular relates to the use of a thioimidazolidinone drug in the treatment of COVID-19 disease. Background technique [0002] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a severe respiratory disease caused by an outbreak called coronavirus disease 2019 (COVID-19) in December 2019. SARS-CoV-2 belongs to the betacoronaviruses, the same as SARS-CoV and MERS-CoV. The characteristics of SARS-CoV-2 are highly similar to SARS-CoV. The key to the infection of human cells by the new coronavirus lies in the combination of the S protein (Spike Glycoprotein, TMPRSS2) of the coronavirus and the ACE2 protein (Angiotensin-converting enzyme 2, angiotensin converting enzyme 2) in the human body (Letko , M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B beta-coronaviruses. Nat. Microbiol. 5, 562–569 (2020)), ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4439A61K31/4164A61K31/58A61K31/277A61K31/4155A61K31/09A61K31/4188A61P31/14
CPCA61K31/4439A61K31/4164A61K31/58A61K31/277A61K31/4155A61K31/09A61K31/4188A61P31/14A61K2300/00
Inventor 童友之马连东周千翔严红花任志华杨剑飞
Owner SUZHOU KINTOR PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com